This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

How Teva Pharmaceutical Is Attacking the Generics to Defend Its Turf

Stocks in this article: TEVA

NEW YORK (TheStreet) -- Teva Pharmaceutical's ADR (TEVA) continues to benefit from the delay in FDA approval of a generic version of its top-selling multiple sclerosis drug Copaxone. The approval delay has given Teva more time to switch patients to a new, three-times-per-week version of the drug.

A low-cost version of Copaxone will be approved eventually, and bulls and bears argue over how much of an impact this will have on the stock's valuation.

At Tuesday's close at $54.95, shares of Teva are up 37% for the year and just short of the 52-week high of $55.24. Teva reports second-quarter earnings on July 31. Here's what to listen for.

Yellen's Testimony Tanks; Trade, Don't Invest: Best of Kass

10 Best Used Luxury Cars Under $30,000

What Would a Tesla-BMW Deal Look Like?

Here's How You Invest in Your Ice Cream and Eat It, Too

As the FDA mulls over the generic version of Copaxone, Teva is taking steps to develop new drugs in its pipeline. It is also pursuing acquisitions in order to make up for any lost revenue due to generic Copaxone.

Wall Street is expecting Teva to report earnings of $1.19 per share, flat from one year ago, on a 3% year-over-year bump in total revenue to $5.06 billion. So far this year, Teva has maintained its 2014 revenue guidance in the range of $19.3 billion to $20.3 billion, which at the midpoint represents a drop of 2.5% from 2013.

Bulls will need reassurance that Teva's drug lineup can withstand FDA approval of generics. But bears will be looking for signs that the party is over.

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs